Conventional cytogenetics is a method to analyze chromosomes. Researchers and clinicians use conventional cytogenetics to diagnose blood disorders, predict outcomes in patients with these disorders, and develop new treatments that target genetic changes associated with a disease.
Bridging the Overlap Gap: Understanding the Natural History of Myelodysplastic/ Myeloproliferative Neoplasm (MDS/MPN)
Different types of MDS/MPN have similar symptoms but profoundly different outcomes. The type and intensity of treatment must be tailored to each patient’s type of MDS/MPN. Therefore, it is important to diagnose these diseases accurately.
Bone marrow biopsies have been described by some as “medieval torture.” Certainly, they can be painful, so why do MPN patients need to have bone marrow biopsies? What are doctors and researchers looking for? Drs. Srdan Verstovsek and Jason Gotlib discuss the necessities of bone marrow biopsies for MPN patients: why we need them, what they accomplish, and how they fit into the total diagnostic process.
In this third video in the series, Myeloproliferative Neoplasms 2015, Ruben Mesa, M.D., professor and hematologist at Mayo Clinic in Arizona, discusses updates on the treatment and management of polycythemia vera as well as shares highlights from the 56th Annual American Society of Hematology (ASH) meeting in San Francisco, December 2014.
In this final video in the series, Myeloproliferative Neoplasms 2015, Ruben Mesa, M.D., professor and hematologist at Mayo Clinic in Arizona, discusses updates on the treatment and management of essential thrombocythemia as well as shares highlights from the 56th Annual American Society of Hematology (ASH) meeting in San Francisco, December 2014.
Dr. Ruben Mesa, Mayo Clinic Cancer Center provides an update on the latest advances in MPN for the Summer 2015
In the following video, Ruben Mesa. M.D., deputy director, Mayo Clinic Cancer Center, provides an update on the latest advances in MPN (Myeloproliferative Neoplasm) treatments from the Summer Medical Meeting (American Society of Clinical Oncology (ASCO) and European Hematology Association Meeting (EHA)).
Dr. Mesa discusses key MPN updates from the American Society of Clinical Oncology (ASCO) meeting in Chicago and the European Hematology Association(EHA) meeting.
Dr. Ruben Mesa (@mpdrc) gives updates from the 2016 American Society of Hematology relevant to the treatment of essential thrombocythemia, polycythemia vera, myelofibrosis and systemic mastocytosis.